Premium
Attrition‐Enhanced Deracemization of the Antimalaria Drug Mefloquine
Author(s) -
Engwerda Anthonius H. J.,
Maassen Rick,
Tinnemans Paul,
Meekes Hugo,
Rutjes Floris P. J. T.,
Vlieg Elias
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201811289
Subject(s) - mefloquine , enantiomer , drug , malaria , pharmacology , racemic mixture , chemistry , combinatorial chemistry , plasmodium falciparum , stereochemistry , medicine , immunology
Mefloquine is an important drug for prevention and treatment of malaria. It is commercially available as a racemic mixture, wherein only one enantiomer is active against malaria, while the other one causes severe psychotropic effects. By converting the drug into a compound that crystallizes as a racemizable racemic conglomerate, the deracemization of mefloquine into the desired enantiomer was achieved.